Table 5 Summary of consistency and completeness of MIP guidance among country-level documents (numerator is number of documents in each country with information about the MIP element, denominator is number of documents reviewed in a given country)

IPTp timing

4/4 documents are consistent, in accordance with 2004 WHO/Africa Regional Office Guidelines

2/4 documents give consistent information on timing; 1/4 is in accordance with WHO

3/9 documents do not specify timing or number of doses; 6/6 documents that mention timing are not in accordance with WHO; 3/6 documents that mention number of doses recommend two doses of SP, and 3/6 recommend 3 doses

4/4 documents are consistent on timing, though not in accordance with WHO; 75% state to give two doses of IPTp, 25% do not specify number

No consistency among five documents: one does not specify timing; one specifies first dose at 16 weeks; one at 20–24 weeks; and two in 4^th–6^th months

IPTp dose (SP, 3 tablets, at least 2 doses one month between doses)

1/4 documents specify correct dose; 1/4 recommend use of SP in certain geographic areas

4/4 documents state correct SP dose

3/9 documents state SP dose

4/4 documents state correct SP dose

3/5 documents state correct SP dose

Prevention and treatment of anaemia

3/4 recommend suspension of folic acid for 14 days after SP

1/4 recommends suspension of folic acid for one week after SP

DOT

4/4 documents recommend DOT

4/4 documents recommend DOT

9/9 documents recommend DOT

4/4 documents recommend DOT

3/4 documents recommend DOT

Linkage to HIV

4/4 documents recommend not giving SP to HIV-positive women on CTX

1/4 documents recommends not giving SP to HIV-positive women on CTX; two do not mention HIV-positive pregnant women; one states that they should receive three doses of IPTp

7/9 documents do not specify management of HIV-positive women; two state that women on CTX or antiretrovirals should not receive IPTp-SP

1/4 documents recommend not giving SP to HIV-positive women on CTX; 2/4 do not mention HIV-positive pregnant women; 1/4 documents is unclear

3/4 documents do not mention HIV-positive pregnant women; one document states need for three doses of IPTp, but incomplete guidance about use of SP for women on CTX

ITN counselling

4/4 documents recommend counselling

4/4 documents recommend counselling

6/9 documents recommend counselling

4/4 documents recommend counselling

4/4 documents recommend counselling

ITN distribution to pregnant women during ANC

2/4 documents specify distribution

3/4 documents specify distribution

3/9 documents specify distribution

1/4 documents specify distribution

1/4 documents specifies distribution

Diagnostic testing

3/4 documents recommend testing, 1/4 do not mention testing

4/4 documents recommend testing

8/9 documents recommend testing

4/4 documents recommend testing

3/4 documents recommend testing (only RH policy does not mention); one document recommending testing also states that any pregnant woman with fever should be treated for malaria even in the presence of a negative blood smear

Treatment of uncomplicated malaria

4/4 documents specify drug to be used; 1/4 documents specifies doses of drugs; 4/4 documents specify drugs by trimester; a; the document that mentions drugs and doses follow WHO treatment guidelines

4/4 documents specify drugs but no document gives doses, while 2/4 documents mention treatment by trimesters; given the incomplete information no document follows WHO treatment guidelines

6/6 documents specify drugs; 4/6 give dose and information by trimester; 2/6 documents are in accordance with WHO treatment guidelines

4/4 documents specify drugs; 2/4 documents state doses and 4/4 mention treatment by trimester; one document is consistent with WHO treatment guidelines

3/3 documents specify drugs, 2/3 mention doses, and 3/3 specify treatment by trimester; 1/3 documents is consistent with WHO guidelines

Treatment of severe malaria

4/4 documents specify drug to be used; 2/4 documents specify doses of drugs; 1/4 documents specifies trimesters. One document follows WHO treatment guidelines.

3/4 documents specify drugs to be used, and 2/4 state the dose, while one refers to treatment by trimester. One document follows WHO treatment guidelines.

6/6 documents specify drugs, 4/6 give doses and 5/6 specify trimesters. 3/6 documents follow WHO treatment guidelines.

4/4 documents specify drugs and doses; 3/4 specify treatment by trimester; no document is consistent with WHO treatment guidelines.

2/3 documents specify drugs, 1/3 gives doses, and 1/3 specifies treatment by trimester. No document is consistent with WHO treatment guidelines.